Amplia has today released its Appendix 4C Cash Flow Report for the quarter ending 31 December 2021.
Key Highlights from the Quarter
- Released supplementary data from the Phase 1 clinical trial confirming that orally administered AMP945 is able to inhibit target FAK in human subjects
- Completed the manufacture of a 2 kg batch of clinical grade AMP945 for use in upcoming preclinical studies and Phase 2 clinical trials
- Appointed internationally renowned drug developer Dr José Iglesias as Clinical Advisor
- $12.4M capital raise and an additional $3.2M from the R&D tax rebate program to support Phase 2 clinical trials planned for 2022
Amplia’s CEO and Managing Director, Dr John Lambert, commented:
“In this last quarter for the year, we have put in place all the resources to make 2022 a watershed year for the Company. We now have a very robust package of preclinical and clinical data on AMP945 that supports the clinical strategy we are taking as we initiate our Phase 2 program for the drug, with the first trial scheduled to start this quarter.”
Click here to read today’s ASX release.
